Johnson & Johnson (NYSE:JNJ) Gains FDA Fast Track For Nipocalimab In Treating Sjogren's Disease
Johnson & Johnson (NYSE:JNJ) experienced an 11% share price increase over the last quarter, coinciding with pivotal ...
Jim Cramer Says Johnson & Johnson (JNJ) Stock Could Fall to $160 Level
We recently published a list of Jim Cramer’s Latest Stock Moves: Top 10 Calls. In this article, we are going to take a look ...
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for ...
Johnson & Johnson (JNJ): “Breakout or Breakdown?” – Jim Cramer Says JNJ Must Fall for Market to Bottom
We recently published a list of Jim Cramer Discusses These 11 Stocks & Says Trump’s ‘Soft’ On Tariffs Amidst $4 Trillion ...
J&J gets FDA Fast Track status for nipocalimab in Sjogren's
Johnson & Johnson (NYSE:JNJ) said on Tuesday that it received U.S. FDA's Fast Track designation for nipocalimab to treat adult patients with moderate-to-severe Sjögren's disease. In November last year ...
Is Johnson & Johnson (JNJ) the Best Dividend Stock to Buy According to Billionaires?
We recently published a list of 25 Best Dividend Stocks to Buy According to Billionaires. In this article, we are going to ...
Johnson & Johnson (NYSE:JNJ) Goes to Court for Third Time over $10B Talc Bankruptcy Plan
Johnson & Johnson (JNJ) begins on Tuesday its third attempt to push through a multi-billion-dollar settlement relating to claims its baby ...
Johnson & Johnson (JNJ) Receives a Buy from RBC Capital
In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), ...
Nasdaq2d
Guru Fundamental Report for JNJ
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...